PTD-DBM

Skin & Hair

aka Protein Transduction Domain-Dishevelled Binding Motif · CXXC5-Dvl interaction antagonist

Compare

Formula

—

MW (Da)

—

Half-life

—

Saves

Overview

PTD-DBM is a synthetic, cell-penetrating competitor peptide engineered to disrupt the CXXC5-Dishevelled (Dvl) protein-protein interaction. By displacing CXXC5 — a negative feedback regulator of Wnt — it reactivates Wnt/β-catenin signaling and downstream wound-healing and follicle-regeneration programs. No human clinical data identified.

Mechanism

CXXC5 is a negative-feedback regulator of Wnt/β-catenin signaling. PTD-DBM disrupts CXXC5 binding to Dvl/Dishevelled, which reactivates β-catenin signaling and downstream wound-healing and follicle-regeneration programs. Primary studies report increased β-catenin, α-SMA, and collagen I in human dermal fibroblasts after PTD-DBM exposure. In wound-healing models PTD-DBM increased Wnt-reporter activity, collagen secretion, gel contraction, and scratch-wound closure. In hair-regeneration models, disrupting the CXXC5-Dvl interaction accelerated hair regrowth and wound-induced follicle neogenesis. A 2023 alopecia study showed topical PTD-DBM helped reverse DHT/PGD2-associated hair loss.

0

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Increased β-catenin, collagen I, and wound-healing markers in fibroblasts

2 or 10 μM PTD-DBM applied to human dermal fibroblasts for 2 days increased β-catenin, α-SMA, type I collagen, Wnt reporter activity, collagen secretion, gel contraction, and scratch-wound closure.

[ptd-dbm-lee-2015]

preclinical

Hair regrowth in mouse alopecia models

Disrupting the CXXC5-Dvl interaction accelerated hair regrowth and wound-induced hair-follicle neogenesis. A 2023 study showed topical 10 mM PTD-DBM every other day helped reverse DHT/PGD2-associated hair loss.

[ptd-dbm-ryu-2023]

preclinical

Reported side effects

No human safety data
anecdotal
Human safety, adverse-event incidence, dose-ranging, and pharmacokinetics are not established. No clinical product label or validated storage standard exists.

Dosing notes

No validated human dose. Preclinical work used 2 or 10 μM in fibroblast culture and topical 10 mM every other day in mouse hair-loss models. Human pharmacokinetics are not established.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

No authoritative clinical storage monograph exists. Any vendor-specific reconstitution rule should be treated as supplier-specific rather than authoritative.

Vendors carrying PTD-DBM

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about PTD-DBM.

No questions yet. Be the first to ask.

References

[ptd-dbm-lee-2015]
The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing (Lee et al. 2015)
Lee SH et al. · 2015 · Journal of Experimental Medicine
Source
[ptd-dbm-pmc-4493411]
PTD-DBM mechanism and fibroblast wound-healing data
Authors per PMC entry · PubMed Central
Source
[ptd-dbm-ryu-2023]
Ryu et al. 2023 — topical PTD-DBM in DHT/PGD2 alopecia model
Ryu Y-C et al. · 2023 · PubMed Central
Source
[ptd-dbm-lee-2017]
Lee et al. 2017 — CXXC5-Dvl follow-up
Lee SH et al. · 2017 · PubMed
Source